Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Inventory (2020 - 2025)

Bioventus' Inventory history spans 6 years, with the latest figure at $82.2 million for Q4 2025.

  • For Q4 2025, Inventory fell 11.07% year-over-year to $82.2 million; the TTM value through Dec 2025 reached $82.2 million, down 11.07%, while the annual FY2025 figure was $82.2 million, 11.07% down from the prior year.
  • Inventory reached $82.2 million in Q4 2025 per BVS's latest filing, down from $96.3 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $97.6 million in Q3 2023 to a low of $34.0 million in Q3 2021.
  • Average Inventory over 5 years is $78.8 million, with a median of $87.8 million recorded in 2023.
  • Peak YoY movement for Inventory: skyrocketed 111.84% in 2021, then fell 11.07% in 2025.
  • A 5-year view of Inventory shows it stood at $61.7 million in 2021, then skyrocketed by 37.41% to $84.8 million in 2022, then grew by 7.75% to $91.3 million in 2023, then grew by 1.25% to $92.5 million in 2024, then dropped by 11.07% to $82.2 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Inventory are $82.2 million (Q4 2025), $96.3 million (Q3 2025), and $96.5 million (Q2 2025).